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ABSTRACT
Objective: To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody
(AQP4-Ab)–mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine
receptor antibody (AChR-Ab)–mediated myasthenia gravis (AChR-MG).
Methods: The clinical details and antibody results of 16 patients with AChR-MG and AQP4-
NMOSD were analyzed retrospectively.
Results: All had early-onset AChR-MG, the majority with mild generalized disease, and a high
proportion achieved remission. Fifteen were female; 11 were Caucasian. In 14/16, the MG pre-
ceded NMOSD (median interval: 16 years) and 11 of these had had a thymectomy although 1 only
after NMOSD onset. In 4/5 patients tested, AQP4-Abs were detectable between 4 and 16 years
prior to disease onset, including 2 patients with detectable AQP4-Abs prior to thymectomy.
AChR-Abs decreased and the AQP4-Ab levels increased over time in concordance with the rele-
vant disease. AChR-Abs were detectable at NMOSD onset in the one sample available from 1 of
the 2 patients with NMOSD before MG.
Conclusions: Although both conditions are rare, the association of MG and NMOSD occurs much
more frequently than by chance and the MG appears to follow a benign course. AChR-Abs or
AQP4-Abs may be present years before onset of the relevant disease and the antibody titers
against AQP4 and AChR tend to change in opposite directions. Althoughmost cases hadMGprior
to NMOSD onset, and had undergone thymectomy, NMOSD can occur first and in patients who
have not had their thymus removed. Neurology® 2012;78:1601–1607
GLOSSARY
Ab antibodies; AChR-Ab acetylcholine receptor antibody; AChR-MG acetylcholine receptor antibody–mediated myas-
thenia gravis; AQP4-Ab  aquaporin-4 antibody; AQP4-NMOSD  aquaporin-4 antibody–mediated neuromyelitis optica
spectrum disorder; IgG  immunoglobulin G; IS  immunosuppressive; LETM  longitudinally extensive transverse myelitis;
MGmyasthenia gravis;NMO neuromyelitis optica;NMOSD neuromyelitis optica spectrum disorder;OCB oligoclonal
bands; ON optic neuritis; SLE systemic lupus erythematosus; VGKC voltage-gated potassium channel.
Neuromyelitis optica (NMO) is a recurrent inflammatory and demyelinating CNS disorder
that affects predominantly the optic nerve and spinal cord.1 In the majority of patients, the
disease is associated with immunoglobulin G1–complement activating antibodies (Ab) against
aquaporin-4 (AQP4).2–4 The detection of these antibodies helps distinguish between NMO
and other inflammatory and autoimmune disorders of the CNS2,4 and characterizes a form of
NMO spectrum disorder (NMOSD) that includes spatially limited forms of disease such as
longitudinally extensive transverse myelitis (LETM) or optic neuritis (ON).5,6 The pathogenic-
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ity of the antibodies has been shown by pas-
sive transfer in different animal models,7–9 as
reviewed elsewhere.10
Myasthenia gravis (MG) is a well-recognized
antibody-mediated disease affecting the neu-
romuscular junction, caused in around 85%
of patients by immunoglobulin G (IgG)1-
and IgG3-complement activating antibodies
against the nicotinic acetylcholine receptor
(AChR, AChR-Ab); for review, see Hoede-
maekers et al.11
Both AQP4-Ab-positive NMOSD and
AChR-Ab-positive MG are associated with
other autoimmune diseases and autoantibod-
ies, both organ-specific and systemic.5,12–15
Despite the rarity of MG and of NMO, sev-
eral cases or small series of patients with both
disorders have been reported over the years,
most published prior to the identification of
AQP4-Abs. In the English language litera-
ture, only 7 cases of AChR-Ab positive MG
and AQP4-Ab-positive NMO/NMOSD have
been reported.16–20
Here we describe 16 patients with MG and
NMOSD from 9 neurology centers around
the world, and describe the clinical features,
serologic, and temporal associations of the
diseases.
METHODS Clinical data. Sixteen patients with MG with
AChR-Abs and NMOSD with AQP4-Abs were identified
from the databases of neurology centers in the United King-
dom, Brazil, Portugal, Japan, and Argentina. One patient
with AChR-MG and NMO-IgG seronegative NMOSD was
not included because serum was not available to be tested for
AQP4-Abs. Data on the clinical features, associated diseases,
investigation results, treatments, and outcomes were collected
from the patients’ notes. All additional serum samples avail-
able from those patients were tested for AChR and AQP4
antibodies.
Standard protocol approvals, registrations, and patient
consents. This retrospective study was approved by the Medi-
cal Ethics Committee of each center and conducted in accor-
dance with the ethical standards recognized internationally.
Written consent to collect and use anonymized clinical data, as
well as serum and thymus tissue, was obtained from each patient
prior to the study.
RESULTS Eight of the 16 patients were identified
from the UK NMO service. Fifteen of the 16 were
female, and 11 were Caucasian. The clinical and lab-
oratory data of each patient are summarized in table
e-1 and table e-2 on the Neurology® Web site at
www.neurology.org. Figure 1 illustrates the timing of
the thymectomy and the NMOSD onset in relation
to the onset of MG for each patient.
Myasthenia gravis features. MG onset occurred be-
tween the ages of 12 and 47 years (median: 26.5) and
all patients were positive for AChR antibodies. The
time to the diagnosis of MG ranged from 0 to 3 years
(median 0.5). The initial presentation was typical
with ocular muscle weakness in 14 patients, and all
but 3 became generalized over time. In general the
MG was mild to moderate (at maximal severity none
of the patients had respiratory symptoms, and none
required intensive care/respiratory support, except
perioperatively related to thymectomy) and, in 6 pa-
tients, the response to pyridostigmine was sufficient
to control their myasthenic symptoms. Nine patients
required immunosuppressive medications such as
oral steroids with or without azathioprine. IV immu-
noglobulin and plasma exchange was only required
early on in the disease course. Thymectomy was per-
formed in 11 of the 13 patients with generalized
MG. Time to thymectomy varied from 1 to 13 years
(median 2) after MG onset. Eight patients had thy-
mic hyperplasia; the remaining 3 had normal histol-
ogy. All responded well to treatments, as seen by
their MGFA score at maximal severity and MGFA
postintervention status (table e-1).
Myasthenia gravis in relation to the presentation and
course of NMOSD. In 14/16 patients, the MG pre-
sented prior to NMOSD, and the time between the
onset of both conditions ranged from 1 to 41 years
(median 16). Among those 14 patients, only 11 were
Figure 1 Time, in years, to thymectomy and to neuromyelitis optica spectrum
disorder (NMOSD) onset in relation to themyasthenia gravis (MG)
onset for each patient
Patients are numbered as in the tables. MG onset: time point 0; red triangle: thymectomy;
green dot: NMOSD onset.
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thymectomized, 10 before NMOSD onset (3 to 30
years of interval; median 11 years) and 1 after. Seven
of those 14 patients needed immunosuppression for
their MG, but 4 had stopped that treatment between
2 and 16 years prior to the NMOSD onset; only 3
were still taking immunosuppression at a low dose
when NMOSD presented. There was no correlation
between timing of discontinuation of immunosup-
pressive treatment for MG and time to onset of
NMOSD. Eleven had minimal myasthenic symp-
toms or had been in remission for months to 25 years
at the time of NMOSD presentation. At the onset of
NMOSD, MG was quiescent and remained so in all
but 2 patients who had a mild exacerbation of myas-
thenic symptoms. There was no clinical evidence of
deterioration or flare up of any of the other associ-
ated autoimmune conditions at, or following onset
of, NMOSD, nor was there any clinical evidence of
new autoimmune diseases.
The other 2 patients developed MG 6 and 24
years after the first manifestations of NMOSD.
These patients were not thymectomized. Both pa-
tients were taking azathioprine at low dose when the
MG started. There was no apparent exacerbation of
NMOSD at the MG onset.
NMOSD features. The clinical presentation of
NMOSD occurred between the ages of 23 and 67
years (median 39.5). All patients were positive for
AQP4-Abs using the cell-based assay previously de-
scribed.2,21 In the first 10 patients, the median time
from onset of NMOSD to serologic diagnosis was 4
years, but in the 6 recently diagnosed patients the
delay did not exceed 1 year. The initial NMOSD
symptoms were ON in 8 patients (1 bilateral ON
and 7 unilateral ON) and TM (associated with
LETM) in the other 8. The disease was monophasic
in 3 patients (2 had severe ON and 1 had LETM); 1
of them was already on steroid treatment for her
MG, another started immunosuppression immedi-
ately after the NMOSD onset attack, and the third
started immunosuppression 4 years after the onset
symptoms when the diagnosis was made. Their
follow-up times ranged from 6 months to 6 years
from NMOSD onset.
In the 13 patients with relapsing disease, 4/13 had
relapses affecting the same system (rON in 2 and
rLETM in 2), whereas 9 experienced attacks involv-
ing both optic nerve and spinal cord fulfilling the
diagnostic criteria for NMO.
Brain MRI was performed during the first at-
tack in 13 patients, and was normal in 10 except
for increased T2 signal in the optic nerve or the
optic chiasm in 4. The other 3 patients had small
nonspecific/vascular white matter lesions. Spinal
cord MRI showed LETM in all the patients who
had transverse myelitis. CSF examination was per-
formed in 10 patients, of whom 1 had positive
oligoclonal bands (OCB) and 4 had a mild pleocy-
tosis. We did not find any obvious relationships
between the NMOSD features and the MG char-
acteristics or treatments, such as thymectomy.
Treatments and evolution of NMOSD. In general, all
patients responded well to immunosuppressive (IS)
therapy (reduction in relapse rate), that was started
(or increased) at variable times in the disease course.
At the last visit, all 15 patients with available treat-
ment information were on IS, the majority on a com-
bined regimen of prednisolone and azathioprine.
Despite this, a considerable proportion of patients
had profound deficits: overall, 10 out of the 16 pa-
tients were blind in at least 1 eye or unable to walk.
One patient died of complications related to severe
NMO at age 54 (12 years post NMO onset and 28
years post MG onset). The disability at last follow-up
did not correlate with the age at onset of any of the
diseases, the severity of MG, or whether or not they
had undergone thymectomy. However, patients with
longer disease duration and delayed diagnosis were
more disabled.
Evidence of antibodies preceding the onset of the dis-
eases: AQP4 and AChR antibodies. Four of the 5 pa-
tients on whom stored serum samples were available
had AQP4-Abs for 4 to 16 years before onset of
NMOSD (patients 3, 8, 1, and 4) (figure 2, A–E). In
2 patients, AQP4-Abs were detectable at the time of
presentation of MG and prior to thymectomy (8 and
16 years before first manifestation of the NMOSD).
In all 5 cases, the AQP4-Ab levels increased until
NMOSD onset, whereas the AChR-Abs declined
following treatments for their MG, although remain-
ing positive as is usually observed. The MG at
NMOSD onset was in remission in 2 of these and
mild in 3 and only 1 was still on low-dose immuno-
suppression. Similarly, the only patient with serum
available, whose NMOSD presented before MG (pa-
tient 13), had detectable AChR-Abs at the time of
NMOSD presentation.
Other associated autoimmunity. Thirteen patients
had laboratory manifestations of other autoimmu-
nity, 7 of whom had clinical manifestations. Of
these, 5 patients had autoimmune thyroid disease
with thyroid peroxidase antibodies and hypothyroid-
ism, treated with thyroxine; 1 patient had mild/
moderately severe systemic lupus erythematosus
(SLE); and 1 had had an episode of limbic encephali-
tis and neuromyotonia associated with voltage-gated
potassium channel complex (VGKC) antibodies. In
the latter case the VGKC antibodies fell rapidly after
treatment, as is usual for these antibodies when
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Figure 2 Sequential titers of serum autoantibodies against acetylcholine receptor (AChR) and aquaporin-4 (AQP4) (A–D) and also against
voltage-gated potassium channel (VGKC) (E), and their correlation with clinical manifestations and treatments of the
respective diseases (myasthenia gravis [MG], neuromyelitis optica spectrum disorder [NMOSD], and limbic encephalitis [LE])
Clinical features of each of the diseases in all patients illustrated were temporally correlated with high titers of the respective antibodies. In all patients,
acetylcholine receptor antibody (AChR-Ab) titerswere highest in the first sample available (in themajority of patients at theMGonset orMGdiagnosis), and
decreased followingMG treatments (either thymectomy or immunosuppression or both). AQP4-Ab titers were low in 3 patients (A, patient 3; B, patient 8; E,
patient 4) or undetectable in 2 patients (C, patient 2; D, patient 1) in the first sample tested. Regardless of the treatment for LE orMG, AQP4-Ab titerswere
increased at NMOSD onset (C, patient 2) or increased throughout up to 16 years (A, patient 3), peaking at the first manifestations of NMOSD.
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treated adequately.22 The remaining 6 patients had 1
or more autoantibodies, predominantly antinuclear,
anti-DNA, antithyroid peroxidase, and anticardioli-
pin antibodies. In the majority of cases, the associ-
ated autoimmune conditions and laboratory markers
were apparent at the time of presentation with the
primary disease.
A family history of other autoimmune diseases
was recorded in 4 patients, 1 of whom had 3 affected
family members; the diseases were autoimmune thy-
roid disease (3), type I diabetes (2), and rheumatoid
arthritis (1).
Comparison between patients with both early-onset
AChR-MG and AQP4-NMOSD and populations with
each of those diseases alone. The clinical features and
severity of the diseases in patients with both condi-
tions were compared to those in patients with either
disease alone (51 patients with early-onset AChR-
MG23; 106 patients with AQP4-NMOSD24); see ta-
ble e-3. There were no significant differences among
these 3 cohorts apart from an increase in other auto-
immune manifestations in patients with both diseases
compared to the AChR-MG cohort (p 0.0001) and
a trend when compared to AQP4-NMOSD alone
(p 0.0146 [p 0.0026 is significant after Bonfer-
roni correction for multiple comparisons]). The pa-
tients with both diseases tended to have milder MG
than patients with AChR-Ab MG only (p 
0.0058). There was a greater female predominance in
the group of patients with both diseases than in those
with either of the diseases, although this difference
was not statistically significant after Bonferroni
correction.
DISCUSSION We describe a cohort of 16 patients
with 2 rare organ-specific autoimmune diseases me-
diated by 2 distinct antibodies, to AChR and to
AQP4, which are both predominantly IgG1 comple-
ment activating antibodies.2,25,26 The features of the 2
diseases were typical, although the MG tended to be
relatively mild and treatment responsive.
Among the few English-language publications of
patients with MG and demyelinating CNS diseases,
only 7 patients were known to have antibody-
positive MG and NMO.16–20 The prevalence of
early-onset AChR-MG (rather than late-onset MG,
which is now much more common) is about 6.2:
100,000 (Carr and McConville, in preparation) and
AQP4-NMOSD prevalence is about 2.7:100,000.27
Thus by chance one would expect only 1:600 mil-
lion. Since the population of the United Kingdom is
66 million, the existence of 8 UK cases is approxi-
mately 70 times higher than expected by chance
(based on the prevalence of the individual diseases),
suggesting a predisposition to autoimmunity in these
patients.
AQP4-NMOSD is recognized to be associated
with other autoimmune manifestations in about
25%–50% of cases, both organ-specific and sys-
temic. These include SLE, Sjo¨gren syndrome, rheu-
matoid arthritis, autoimmune thyroid disease, and
their respective antibodies.12,13,28 The same associa-
tions are reported in MG, although less frequently
(5%–30%) with thyroid autoimmunity, particularly
Graves disease, predominating.14,15 In our series,
44% of the patients had clinical and laboratory fea-
tures of thyroiditis with hypothyroidism associated
with thyroid peroxidase Abs, and 81% had clinical or
laboratory evidence of other autoimmune conditions
such as Sjo¨gren syndrome, SLE, or antiphospholipid
syndrome. This is significantly higher than their fre-
quency in isolated NMOSD or MG, further reflect-
ing an increased risk of multiple autoimmune
manifestations in this subgroup of patients.12–15,28
In 90% of our patients, MG preceded NMOSD,
and nearly 70% had had a preceding thymectomy
(as is standard treatment in early-onset generalized
AChR-MG), as was found in all 6 previous AChR-Ab
and AQP4-Ab positive cases reported.16–20 The thy-
mic pathology showed the expected hyperplasia in
the majority of our patients but was normal in some.
Although 81% of our patients had generalized MG,
none were severely affected and a high proportion
achieved remission. It was rare for the MG to relapse
once NMOSD developed, and the AChR-Ab levels
correlated with the MG clinical course. However,
more severely affected AChR-MG patients may be
on more aggressive treatment that could prevent the
clinical expression of NMOSD. A screening of pa-
tients with MG for AQP4-Abs is needed to clarify
this finding.
A link between the thymus gland and MG has
been demonstrated previously. Human thymus tis-
sue has been shown to express AChR,29,30 which is
widely thought to be a triggering mechanism in
early-onset AChR-MG.31–33 Recent evidence suggests
that AQP4 is also expressed in human thymus34
(Marx and Strobel, unpublished data; Leite and Vin-
cent, unpublished data), suggesting a similar, and
early, involvement of the thymus in NMOSD; this is
supported by our findings of AQP4-Abs being de-
tectable years prior to the onset of NMOSD, includ-
ing at MG onset.
The clinical and laboratory features of the indi-
vidual diseases and their time courses remain un-
changed in patients with both conditions suggesting
coincident diseases. However, the relative increase in
prevalence of patients with both AQP4-NMOSD
and AChR-MG suggests these patients have a predis-
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position to autoimmunity, but the dynamics of the
individual diseases remain unchanged. An interesting
finding in this study was the frequent detection of
antibodies associated with a second autoimmune dis-
ease many years before any clinical signs. This study
also implies that the thymus may have a role in the
immunopathogenic mechanisms triggering those 2
diseases and possibly other associated autoimmune
manifestations, but could not find clear evidence for
the role of thymectomy on the development of
AQP4-NMOSD.
Given the risk of concurrent autoimmune dis-
eases in patients with either MG or NMO, we sug-
gest routine evaluation of thyroid antibodies, and
where possible, AQP4-Abs in all patients with early-
onset AChR-MG. When AQP4-Abs are detected in
patients with MG without symptoms of NMO, care-
ful observation is strongly encouraged and patients
should be warned of a possible increased risk of
developing other antibody-mediated conditions.
NMOSD should be first considered in patients with
MG who develop inflammatory demyelinating con-
ditions of the CNS, and their sera should be tested
for AQP4-Abs. In cases where sera are AQP4-Ab
negative, other diagnoses such as multiple sclerosis,
seronegative NMO, acute disseminated encephalo-
myelitis, SLE, or Sjo¨gren syndrome may also be con-
sidered. Conversely, the development of MG in 2
patients with a primary diagnosis of NMO, and the
coexistence of other antibody-mediated diseases in
NMO, means that testing for antibodies to AChR
and other autoantigens would be appropriate in pa-
tients with NMO in whom the clinical features were
not fully consistent with the radiologic findings.
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